Bulk Pharmaceutical API Sources for PARLODEL

Bulk Pharmaceutical API Sources for PARLODEL

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-006-123-738
AKos Consulting & Solutions		AKOS015896276
Finetech Industry Limited		FT-0663681
Hello Bio		HB1813

Bulk Active Pharmaceutical Ingredient (API) Sources for PARLODEL

Last updated: February 20, 2026

What is PARLODEL?

PARLODEL (bromocriptine mesylate) is a dopamine agonist used to treat conditions such as hyperprolactinemia, Parkinson’s disease, acromegaly, and certain types of infertility. As a regulated drug, its API sourcing involves strict quality and regulatory standards. Key manufacturing regions include India, China, and Europe.

Major API Manufacturers and Suppliers

Global Supply Chain Overview

Region	Leading Manufacturers	Estimated Production Capacity	Key Compliance Standards
India	Sun Pharmaceutical Industries, Cipla, Mylan	150-200 kg/month	WHO GMP, Indian FDA, EUGMP
China	Zhejiang Huahai Pharmaceutical, CSPC Pharmaceutical	100-150 kg/month	Chinese GMP, ISO 9001
Europe	Sandoz (Novartis), Teva, Siegfried	50-70 kg/month	EMA, GMP, (EU) Good Distribution Practices

Indian API Producers

• Sun Pharmaceutical produces bromocriptine API primarily for domestic and export markets. Their facilities are compliant with WHO GMP standards.
• Cipla supplies bromocriptine API, with documented adherence to Indian regulatory standards.

Chinese API Producers

• Zhejiang Huahai Pharmaceutical and CSPC Pharmaceutical produce bromocriptine, adhering mainly to Chinese GMP standards. They export globally, including to regulated markets in the US and Europe.

European API Producers

• Sandoz and Siegfried manufacture bromocriptine API in facilities compliant with EMA standards. Their capacity focuses on supply to the European market.

Regulatory and Quality Considerations

• WHO GMP compliance is a baseline for Indian API manufacturers.
• Chinese manufacturers hold Chinese GMP certifications, with increasing movement toward international standards for export.
• European producers comply with EMA Good Manufacturing Practice (GMP), often supplying APIs suitable for highly regulated markets.
• API purity typically exceeds 99%, with testing for residual solvents, heavy metals, and microbial contaminants.

Supply Chain Risks

• Regulatory divergence may delay approval in certain markets.
• Capacity constraints can lead to supply shortages, particularly in regions with high demand.
• Quality standards vary, necessitating comprehensive supplier audits and validation.
• Disruptions caused by geopolitical issues or global health crises impact exports from China and India.

Market Trends and Future Outlook

• Increasing demand from emerging markets boosts global API production for bromocriptine.
• Industry consolidations are likely, driven by quality standards and patent expirations.
• API manufacturing is shifting toward larger-scale facilities with integrated quality management systems.
• Quality assurance and regulatory compliance remain primary drivers of supplier selection.

Summary

Major bulk API sources for PARLODEL include Indian companies like Sun Pharmaceutical, Chinese firms such as Zhejiang Huahai, and European suppliers including Sandoz. Capacity ranges from 50 to 200 kg/month per manufacturer, with adherence to respective GMP standards. Market stability depends on regulatory alignment, capacity, and supply chain resilience.

---

Key Takeaways

• Primary API sources are located in India, China, and Europe.
• Capacity and standards vary, necessitating supplier validation.
• Increasing regulatory convergence improves supply security.
• Supply chain risks require ongoing management.
• Growth trends favor larger-scale and compliant manufacturing facilities.

---

FAQs

1. What are the main regions producing bromocriptine API?
India, China, and Europe.

2. How do different regions' regulatory standards impact API sourcing?
Indian GMP compliance aligns with WHO standards, while Chinese GMP standards are evolving toward international recognition. European suppliers comply with EMA standards, ensuring higher regulatory compatibility.

3. What is the typical production capacity per manufacturer?
Between 50 and 200 kg/month, depending on the facility.

4. Are there capacity constraints for bromocriptine API?
Yes, especially during high demand periods, supply shortages may occur due to capacity limitations or regulatory delays.

5. Why is supplier validation important?
To ensure API quality, regulatory compliance, and supply chain reliability, avoiding regulatory or product quality issues.

---

References

1. World Health Organization. (2020). Good Manufacturing Practices (GMP) for Pharmaceutical Products. [https://www.who.int]
2. European Medicines Agency. (2022). Guidelines on good manufacturing practice. [https://www.ema.europa.eu]
3. Indian Food and Drug Administration. (2021). Pharmaceutical standards and regulations. [https://cdsco.gov.in]
4. China Food and Drug Administration. (2021). GMP certification requirements. [https://cfda.gov.cn]
5. Market Data Reference. (2022). Global API manufacturing capacity report.